The oncolytic virus therapy-based cancer drug developer is based on research at Salk Institute and has raised $77m in its series A round.
IconOVir Bio, a US-based oncology therapy developer based on research at Salk Institute for Biological Sciences, raised $77m in a series A round co-led by Nextech and Vida Ventures today.
GV, a corporate venturing subsidiary of internet and technology conglomerate Alphabet, also took part together with Two River Group, Bellco Capital, Polaris Partners, Wellington Partners Venture Capital and Logos Capital.
IconOVir is developing oncolytic virus therapies that will form the basis of personalised cancer treatments. It was established by Two River Group to advance technology developed by scientific founder Clodagh O’Shea at Salk Institute for Biological Sciences.
The startup’s lead drug candidate, OV-1042 is derived from the common cold virus and could potentially infect and kills tumour cells in areas such as the head, neck, bladder, lung and breast. It aims on submit an investigational new drug (IND) application in early 2022.
Mark McCamish, chief executive of IconOVir, said: “We are committed to designing and developing the next generation of high-potency, tumour-selective oncolytic viruses that can be used in a wide variety of solid tumours, including metastatic disease.
“This can address the major limitations of the only currently marketed oncolytic virus therapy. In pursuit of that goal, and in collaboration with Dr O’Shea, we have created a robust discovery pipeline.
“With our series A financing, raised from the support of premier healthcare investors, we believe we have the financial resources to advance our product candidates into clinical development over the next 18 to 24 months.”
– A version of this article first appeared on our sister site, Global Corporate Venturing.
